Wegovy weight loss results: What 60 lbs in 43 weeks actually means
Quick answer
Priscilla's reported loss of approximately 22.9% of her starting body weight over 43 weeks on semaglutide 2.4mg (Wegovy) exceeds the STEP 1 trial mean of 14.9% but falls within the range of high-responder outcomes documented in that study. Her emphasis on concurrent dietary and exercise changes is consistent with the trial design, which included lifestyle counseling for all participants. The outstanding clinical question she raises, whether to continue the medication indefinitely, is addressed in STEP 4 data showing significant weight regain after discontinuation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @priscilla91_ actually say?
Priscilla says she lost 60 pounds over 43 weeks on Wegovy, dropping from 262 to 202 lbs at 5'7". She pushes back hard against the "easy way out" framing, describing the drug as a "tool" that helped her build better diet and exercise habits. She sidesteps the discontinuation question, saying that's between her and her doctor.
That's a notable rate: roughly 1.4 lbs per week on average. She doesn't claim it was effortless, doesn't recommend a dose, and explicitly tells viewers to talk to their own physician before starting. For a TikTok with 30K views, the restraint here is genuinely unusual. She's not selling anything, and she's not overclaiming.
Does the science back this up?
Her results are at the higher end of what trials show, but they're not implausible. The STEP 1 trial (Wilding et al., 2021, NEJM) found that semaglutide 2.4mg produced mean weight loss of about 14.9% of body weight over 68 weeks in adults with obesity. For someone starting at 262 lbs, that's roughly 39 lbs at the average. Priscilla's 60 lbs over 43 weeks is above the trial average, but individual variation in GLP-1 response is wide.
A few factors explain above-average outcomes. Higher starting weight generally correlates with greater absolute pound loss. Behavioral change on top of the medication amplifies results. Adherence matters too. STEP 1 participants who combined lifestyle intervention with semaglutide outperformed those with minimal behavioral support. Priscilla specifically mentions implementing "better habits for myself with diet and exercise," which is consistent with what drives top-quartile outcomes in the clinical data.
What did they get right (and what's missing)?
She got the fundamentals right. Wegovy is not magic, it does not work without behavioral effort for most people, and whether to stay on it long-term is a legitimate medical conversation. Give her credit there.
What she glosses over is the discontinuation data, and that's a real gap. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that participants who stopped semaglutide after 20 weeks regained two-thirds of their lost weight within a year. That's not a scare tactic, it's the actual pharmacology. Semaglutide suppresses appetite while you're on it. When you stop, that suppression stops. Her answer of "I'll try to maintain healthy habits" is admirable, but the trial data suggests habits alone often aren't enough to hold the loss after stopping. She should know that, and her audience should too.
She also doesn't mention common side effects like nausea, vomiting, and gastrointestinal distress, which affect a majority of users at some point during dose escalation.
What should you actually know?
Sixty pounds in 43 weeks is a real outcome, not a fabrication, but it's not the median outcome either. Most people on semaglutide lose meaningfully less in that timeframe. If you start with that number as your benchmark, you're setting yourself up for frustration.
The more important number to sit with is from the STEP 4 trial: approximately 6.9% of body weight regained within 52 weeks of stopping, with most participants regaining the majority of lost weight over time. GLP-1 drugs appear to be chronic medications for many users, similar in concept to how statins work for cholesterol. That's not a criticism of the drugs, it's just the honest framing. Priscilla's instinct to keep the conversation ongoing with her doctor is exactly right, but viewers deserve to know why that conversation is going to come up again and again.
Also worth noting: semaglutide under the brand Wegovy is FDA-approved specifically for weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. That's the regulatory context her video is living in.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Wegovy weight loss results: What 60 lbs in 43 weeks actually means, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Priscilla's reported loss of approximately 22.
FormBlends verdict
Priscilla's reported loss of approximately 22.9% of her starting body weight over 43 weeks on semaglutide 2.4mg (Wegovy) exceeds the STEP 1 trial mean of 14.9% but falls within the range of high-responder outcomes documented in that study. Her emphasis on concurrent dietary and exercise changes is consistent with the trial design, which included lifestyle counseling for all participants. The outstanding clinical question she raises, whether to continue the medication indefinitely, is addressed in STEP 4 data showing significant weight regain after discontinuation.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Priscilla's reported loss of approximately 22.9% of her starting body weight over 43 weeks on semaglutide 2.4mg (Wegovy) exceeds the STEP 1 trial mean of 14.9% but falls within the range of high-responder outcomes documented in that study. Her emphasis on concurrent dietary and exercise changes is consistent with the trial design, which included lifestyle counseling for all participants. The outstanding clinical question she raises, whether to continue the medication indefinitely, is addressed in STEP 4 data showing significant weight regain after discontinuation.
- The STEP 1 trial (Wilding et al., 2021, NEJM) found mean weight loss of 14.9% of body weight over 68 weeks with semaglutide 2.4mg plus lifestyle intervention. Priscilla's reported 22.9% loss over 43 weeks is above the mean but within the high-responder range.
- STEP 4 data (Rubino et al., 2021, JAMA) showed that stopping semaglutide after 20 weeks led to regain of approximately two-thirds of lost weight within 52 weeks, even with continued lifestyle support.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The STEP 1 trial (Wilding et al., 2021, NEJM) found mean weight loss of 14.9% of body weight over 68 weeks with semaglutide 2.4mg plus lifestyle intervention. Priscilla's reported 22.9% loss over 43 weeks is above the mean but within the high-responder range.
- STEP 4 data (Rubino et al., 2021, JAMA) showed that stopping semaglutide after 20 weeks led to regain of approximately two-thirds of lost weight within 52 weeks, even with continued lifestyle support.
- Wegovy (semaglutide 2.4mg) is FDA-approved for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition like hypertension or type 2 diabetes.
- GI side effects including nausea, vomiting, and diarrhea are reported in over 40% of semaglutide users during dose escalation phases, per STEP trial safety data. Priscilla does not mention this in her video.
- Individual response to semaglutide varies significantly. Starting weight, adherence to behavioral changes, and dose escalation schedule all affect outcomes. Using a single person's result as a benchmark is a poor way to set expectations.
- Compounded semaglutide products are not equivalent to FDA-approved Wegovy or Ozempic. The FDA has warned consumers about variable purity and dosing in compounded versions.
- Long-term use of GLP-1 agonists for weight management is increasingly viewed by endocrinologists as a chronic treatment strategy, similar to antihypertensives, rather than a short-term intervention.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Priscilla Hernandez · TikTok creator
30.1K views on this video
60 pounds down in 43 weeks! 🙌🏼 #wegovy #wegovyupdate #wegovyjourney #wegovyweightloss #semaglutide #semaglutidejourney #glp1 #weightloss #weightlossjourney #weightlossupdate #fyp
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Priscilla Hernandez, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.